NasdaqGS:BIIBBiotechs
Biogen (BIIB) Is Up 9.9% After US$1 Billion RayThera Deal And Salanersen Win - Has The Bull Case Changed?
Earlier this week, Biogen drew attention as Axtria honored its transformation leaders at Axtria Ignite 2026, while the company also advanced its push beyond declining multiple sclerosis and Spinraza sales with newer drugs such as Leqembi, Skyclarys, Qalsody, and Zurzuvae.
More recently, Biogen’s agreement to acquire RayThera Inc. for US$1.00 billion and the FDA’s Breakthrough Therapy designation for Salanersen have highlighted management’s effort to refresh the pipeline just as competition...